Trials / Completed
CompletedNCT01760460
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with dyslipidemia when added to an existing statin-modifying therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anacetrapib | |
| DRUG | Placebo for anacetrapib |
Timeline
- Start date
- 2013-03-14
- Primary completion
- 2015-03-04
- Completion
- 2015-03-04
- First posted
- 2013-01-04
- Last updated
- 2017-06-01
Source: ClinicalTrials.gov record NCT01760460. Inclusion in this directory is not an endorsement.